Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE DM versus TRIPHED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE DM versus TRIPHED.
PROMETHAZINE DM vs TRIPHED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
Triprolidine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby alleviating symptoms of allergic reactions. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing edema.
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
Adults: Triprolidine 2.5 mg / pseudoephedrine 60 mg orally every 4-6 hours, not to exceed 4 doses in 24 hours.
None Documented
None Documented
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
Terminal elimination half-life is 6-8 hours in adults with normal renal function; clinically, dosing interval adjustments are recommended in renal impairment.
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Renal excretion of unchanged drug and metabolites accounting for approximately 60-70% of elimination; biliary/fecal elimination accounts for 20-30%.
Category A/B
Category C
Antihistamine / Antiemetic
Antihistamine/Decongestant Combination